Use of sympathetic alpha antagonists in the management of pediatric urologic disorders

Current Opinion in Urology

Volumn 16, Issue 4, 2006, Pages 277-282

  Husmann, Douglas A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alpha adrenergic antagonists; Neurogenic bladder; Voiding dysfunction

Indexed keywords

ACETYLCHOLINE; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; TAMSULOSIN; TERAZOSIN;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANTIBIOTIC THERAPY; ASTHENIA; BLADDER CAPACITY; BLADDER COMPLIANCE; CHILDHOOD DISEASE; CHLAMYDIA; CLINICAL TRIAL; DETRUSOR DYSSYNERGIA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ELECTROMYOGRAM; FATIGUE; HUMAN; IMPAIRED BLADDER EMPTYING; MUSCLE WEAKNESS; MYCOPLASMA; NEUROGENIC BLADDER; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; URETER STONE; URETHRA; URETHRA DISEASE; URETHRITIS; URINARY FREQUENCY; URINARY TRACT DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CHILD; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NERVOUS SYSTEM DISEASES; RECEPTORS, ADRENERGIC, ALPHA; UROLOGIC DISEASES;

EID: 33745224970     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000232050.89589.e6     Document Type: Review

References (49)

1. Krane R, Olsson C. Phenoxybenzamine in neurogenic bladder dysfunction. I. A theory of micturition. J Urol 1973; 10:650-652.
2. Ruggieri M, Braverman A, Pontari M. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 2005; 174:1743-1748. Good review article on the combined use of alpha-adrenergic antagonists and anticholinergics in the treatment of voiding dysfunction.
3. Gerber G, Kim J, Contreras B, et al. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology 1996; 47:840-843.
4. McConnell J, Roehrborn C, Bautista O, et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.
5. Serels S, Stein M. Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol Urodyn 1998; 17:31-35.
6. Swierzewski S, Gormley E, Belville W, et al. The effect of terazosin on bladder function in the spinal cord injured patient. J Urol 1994; 151:951-954.
7. Somogyi G, Tanowitz M, de Groat W. Prejunctional facilitatory alpha 1-adrenoceptors in the rat urinary bladder. Br J Pharmacol 1995; 114:1710-1715.
8. Yamamoto T, Ghosh R, De Groat W, Somogyi G. Facilitation of transmitter release in the urinary bladders of neonatal and adult rats via alpha1-adrenoceptors. Eur J Pharmacol 2001; 41:31-35.
9. Yoshimura N, Sasa M, Ohno Y, et al. Contraction of urinary bladder by central norepinephrine originating in the locus coeruleus. J Urol 1988; 139:423-426.
10. Danuser H, Thor K. Inhibition of central sympathetic and somatic outflow to the lower urinary tract of the cat by the alpha1-adrenergic receptor antagonist prazosin. J Urol 1995; 153:1308-1311.
11. Birder L, Apodaca G, De Groat W, Kanai A. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 1998; 275:226-F228.
12. Moore C, Levendusky M, Longhurst P. Relationship of mass of obstructed rat bladders and responsiveness to adrenergic stimulation. J Urol 2002; 168:1621-1623.
13. Perlberg S, Caine M. Adrenergic response of bladder muscle in prostatic obstruction. Its relation to detrusor instability. Urology 1982; 20:524-528.
14. Hampel C, Dolber P, Smith M, et al. Modulation of bladder [alpha] 1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002; 167:1513-1518.
15. Restorick J, Mundy A. The density of cholinergic and alpha and beta adrenergic receptors in the normal and hyper-reflexic human detrusor. Br J Urol 1989; 63:32-36.
16. Abrams P, Amarenco G, Bakke A, et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003; 170:1242-1251.
17. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha blocker plus anticholinergic for bladder outlet obstruction: a prospective randomized controlled study. J Urol 2003; 169:2253-2256.
18. Allen T. Forty years experience with voiding dysfunction. Br J Urol 2003; 92:15-22.
19. Sureshkumar P, Craig J, Roy L, Knight J. Daytime urinary incontinence in primary school children: a population-based survey. J Pediatr 2000; 137:814-817.
20. Kramer S, Rathbun S, Elkins D, et al. Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population. J Urol 2005; 173:2121-2124. Well designed double-blind placebo-controlled study on the use of alpha antagonists as primary therapy for voiding dysfunction.
21. Bauer S, Retik A, Colodny A, et al. The unstable bladder of childhood. Urol Clin North Am 1980; 7:321-336.
22. Crimmins C, Rathbun S, Husmann D. Management of urinary incontinence and nocturnal enuresis in attention deficit hyperactivity disorder. J Urol 2003; 170:1347-1350.
23. McKenna P, Herndon C, Connery S, Ferrer F. Pelvic floor muscle retraining for pediatric voiding dysfunction using interactive computer games. J Urol 1999; 162:1056-1062.
24. Metwalli A, Cheng E, Kropp B, Pope JI. The practice of urethral dilation for voiding dysfunction among fellows of the section on Urology of the American Academy of Pediatrics. J Urol 2002; 168:1764-1767.
25. Bani-Hani A, Vandersteen D, Reinberg Y. Neuromodulation in pediatrics. Urol Clin North Am 2005; 32:101-107. Good review article on the use of sacral neuromodulation in the field of pediatric urology.
26. Vignes J, De Seze M, Dobremez E, et al. Sacral neuromodulation in lower urinary tract dysfunction. Adv Tech Stand Neurosurg 2005; 30:177-224. Reviews the use of sacral neuromodulation in urology with a distinct viewpoint from a neurosurgical perspective.
27. Yang S, Wang C, Hsieh C, Chen Y. Alpha1 adrenergic blockers in young men with primary bladder neck obstruction. J Urol 2002; 168:571-574.
28. Yucel S, Akkaya E, Guntekin E, et al. Can alpha-blocker therapy be an alternative to biofeedback for dysfunctional voiding and urinary retention? A prospective study. J Urol 2005; 174:1612-1615. Well written, innovative article comparing and contrasting the ability of alpha antagonists with biofeedback techniques in the treatment of recalcitrant voiding dysfunction.
29. Bogaert G, Beckers G, Lombaerts R. The use and rationale of selective alpha blockade in children with non-neurogenic neurogenic bladder dysfunction. Int Braz J Urol 2004; 30:128-134.
30. Monda J, Husmann D. Primary nocturnal enuresis: a comparison among observation, imipramine, desmopressin acetate and bedwetting alarm systems. J Urol 1995; 154:745-748.
31. Elbadawi A, Atta A. Ultrastructure of the vesicourethral innervation IV. Evidence for somatomotor plus autonomic innervation of the male feline rhabdosphincter. Neurourol Urodyn 1985; 4:23-36.
32. Kumagi A, Koyangi T, Takahashi Y. The innervation of the external urethral sphincter: an ultrastructural study in male subjects. Urol Res 1987; 15:39-43.
33. Kakizaki H, Ameda K, Kobayashi S, et al. Urodynamic effects of alpha 1 blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol 2003; 10:576-581.
34. Koyangi T. Studies on the sphincteric system located in the urethra: the external urethral sphincter revisited. J Urol 1980; 124:400-406.
35. Burnett A, Mostwin J. In situ anatomical study of the male urethral sphincteric complex: relevance to continence following pelvic surgery. J Urol 1998; 160:1301-1306.
36. Docimo SG, Silver RI, Gonzalez R, et al. Idiopathic anterior urethritis in prepubertal and pubertal boys: pathology and clues to etiology. Urology 1998; 51:99-101.
37. Herz D, Weiser A, Collette T, et al. Dysfunctional elimination syndrome as an etiology of idiopathic urethritis in childhood. J Urol 2005; 173:2131-2137. Intriguing paper hypothesizing that dysfunctional voiding is the cause of idiopathic urethritis and that its symptoms may be shortened by using timed voiding and/or alpha antagonists or biofeedback techniques.
38. Kaplan G, Brock W. Idiopathic urethrorrhagia in boys. J Urol 1982; 128:1001-1004.
39. Palagiri A, Steinhardt G, Decter R. A retrospective analysis on the diagnosis and management of idiopathic urethrorrhagia. J Urol 2003; 169:106.
40. Segura JW, Preminger GM, Assimos DG, et al. Ureteral Stones Guidelines Panel summary report on the management of ureteral calculi. The American Urological Association. J Urol 1997; 158:1915-1921.
41. Anderson J, Ogan K, Pearle M. Improving stone passage with medical therapy. Contemp Urol 2006; 18:9-17. Very well written review article outlining the current literature on improving the passage of ureteral calculi with medical therapy.
42. Debella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol 2003; 170:2202-2205.
43. Yilmaz E, Batislam E, Basar M, et al. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol 2005; 173:2010-2012. Well designed research paper evaluating the ability of three different alpha antagonists to aid in the spontaneous passage of ureteral calculi.
44. Donohoe JM, Combs AJ, Glassberg KI. Primary bladder neck dysfunction in children and adolescents II: results of treatment with alpha-adrenergic antagonists. J Urol 2005; 173:212-216.
45. Austin P, Homsy Y, Masel J, et al. Alpha adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. J Urol 1999; 162:1067-1964.
46. Kaplan S. Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function. Urology 2004; 63:428-434.
47. Kirby R, Quinn S, Mallen S, Jensen D. Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. Int J Clin Pract 2004; 58:6-10.
48. de Reijke T, Klarskov P. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int 2004; 93:757-762.
49. Kirby R. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003; 91:41-44.